Repare Therapeutics Inc. has announced a strategic partnership with DCx Biotherapeutics Corporation through an out-licensing agreement. Under this collaboration, Repare will transfer its discovery platforms and certain intellectual property to DCx, a newly-launched Canadian biotechnology firm. The agreement includes upfront and near-term payments totaling $4 million to Repare and grants them a 9.99% equity stake in DCx. Additionally, Repare is eligible for future milestone payments and sales royalties. This partnership allows Repare to concentrate on its clinical portfolio while maintaining an economic interest in the technologies developed. DCx will also acquire lease rights to laboratory facilities in Montreal and retain approximately 20 of Repare's preclinical research employees.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.